Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest - A dose-ranging study

Maturitas

Volumn 35, Issue 3, 2000, Pages 253-261

  Graser T ^a   Muller A ^a   Mellinger, U ^a   Muck A O ^b   Lippert, T H ^b   Oettel, M ^a  

^a BAYER PHARMA AG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Bleeding pattern; Dienogest; Endometrium; Hormone replacement therapy; Low density lipoprotein

Indexed keywords

DIENOGEST; ESTRADIOL VALERATE;

ADULT; AGED; ARTICLE; CLIMACTERIUM; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; ENDOMETRIUM BIOPSY; ESTROGEN THERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UTERUS BLEEDING;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENDOMETRIUM; ESTRADIOL; ESTROGENS, CONJUGATED (USP); FEMALE; GERMANY; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; NANDROLONE; PROGESTERONE CONGENERS;

EID: 0342647017     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(00)00112-2     Document Type: Article

References (16)

1. Sherman A., Brown S. The precursors of endometrial cancer. Am. J. Obstet. Gynecol. 135:1979;947-956.
2. Gambrell R. The menopause. Invest. Radiol. 21:1986;369-378.
3. Whitehead M.I., Fraser D. Controversies concerning the safety of estrogen replacement therapy. Am. J. Obstet. Gynecol. 156:1987;1313-1322.
4. Ettinger B., Golditch I.M., Friedman G. Gynecologic consequences of long-term, unopposed estrogen replacement therapy. Maturitas. 10:1988;271-282.
5. Staland B. Continuous treatment with natural oestrogens and progestogens: a method to avoid endometrial stimulation. Maturitas. 3:1981;145-156.
6. Fink B.J. Endometrial changes after long-term use of continuous oestrogen and cyclic progestogen. Maturitas. 5:1984;277-280.
7. Whitehead M.J., Lobo R.A. Consensus conference: progestogen use in postmenopausal women. Lancet. 8622:1988;1243-1244.
8. Udoff L., Langenberg P., Adashy E.Y. Combined continuous hormone replacement therapy: a critical review. Obstet. Gynecol. 86:1995;306-316.
9. Session D.R., Kelley A.C., Jewelemicz R. Current concepts in estrogen replacement therapy in the menopause. Fertil. Steril. 59:1993;277-284.
10. Weinstein L., Bewtra C.H., Gallagher J. Evaluation of continuous combined low-dose regimen of estrogen-progestin treatment of the menopausal patient. Am. J. Obstet. Gynecol. 162:1990;1534-1542.
11. Høvik P., Sundsbak H.P., Gaasemyr M., Sandvik L. Comparison of continuous and sequential oestrogen-progestogen treatment in women with climacteric symptoms. Maturitas. 11:1989;75-82.
12. Oettel M., Bervoas-Martin S., Elger W. et al. A 19-norprogestogen without a 17α-ethinyl group I: dienogest from a pharmacokinetic point of view. Drugs Today. 31:1995;499-516.
13. Oettel M., Carol W., Elger W. et al. A 19-norprogestogen without a 17α-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today. 31:1995;517-536.
14. Moore C, Walter F, Mellinger U, Zahradnik HP. Multizentrische studie zu kontrazeptiver sicherheit, zyklusbeeinflussung und vertäglichkeit von MP 2000 mikropille - ein zwischenbericht. Dienogest - Präklinik und Klinik eines neuen Gestagens 1995; 2. Auflage.
15. Wren B.G., Brown L. Compliance with hormonal replacement therapy. Maturitas. 13:1991;17-21.
16. Weinstein L. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet. Gynecol. 69:1987;929.